Helping people overcome food allergy: pioneering treatments based on our leading research
Food allergy
Food allergy is a debilitating disease. It can result in a range of symptoms, from mild reactions like itching or hives to severe, life-threatening conditions such as anaphylaxis.
Food allergies affect around 90 million people globally. Common allergens include peanuts, tree nuts, milk, eggs, wheat, soy, fish, and shellfish.
Camallergy is developing a pipeline of products to treat food allergies, starting with peanut allergy.
Peanut allergy: the highest priority
Peanut allergy is highly prevalent. It affects 1.4 to 3% of children and at least 0.5% of adults in high-income countries – around 6 million in Europe and the US.
Peanut allergy is a severe disease. It is the most common cause of severe and fatal allergic reactions related to food. The constant fear of anaphylaxis reduces quality of life.
About Camallergy
Camallergy (Cambridge Allergy Ltd) is a clinical stage biopharmaceutical company dedicated to providing innovative, patient-centric treatments to address the tens of millions of people worldwide who suffer from food allergies.
Our treatment regimens are based on the clinical work initiated at Cambridge University Hospitals NHS Foundation Trust in Cambridge, UK, by the scientific co-founders of the company, Drs Andrew Clark and Pamela Ewan.
Our products have been used by Cambridge Peanut Allergy Clinic to treat more than 200 children in a real world clinical service, transforming patients’ lives.
Camallergy’s new treatments incorporate the Dosage Manager, a medical device developed by Sweden-based OnDosis, which was spun from AstraZeneca in 2017.